On July 16, 2020, Thermo Fisher and QIAGEN … Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. By using this site you agree to the use of cookies for analytics, personalized content and ads. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any ordinary shares of QIAGEN or any other securities, nor is it a substitute for the tender offer materials that Thermo Fisher or its acquisition subsidiary file with the SEC and publish in Germany. READ MORE. With disclosure dated November 11, 2020, QIAGEN N.V. announced pursuant to Article 5 Section (1) and (6) of the EU Regulation no 596/2014 and Article 2 Section (1) of the Delegated EU Regulation no … QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that Dr. Toralf Haag has been appointed a member of the Supervisory Board with immediate effect. QIAGEN CLC new release Check out some of the many new features delivered in the QIAGEN CLC solutions QIAGEN CLC Genomics Workbench 20.0: A host of new features help you scale your research, and allow you to ramp up your productivity by taking your multi-sample analyses to … WALTHAM, Mass.– (BUSINESS WIRE)– TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced the signing of a research license and option agreement with QIAGEN to develop T cell-based laboratory tests for detecting prior exposure to the novel coronavirus, SARS-CoV-2, using discoveries from TScan’s … To the extent that any of the statements contained herein relating to QIAGEN's outlook, products, launches, pipeline, regulatory submissions, collaborations, markets, strategy, employees, taxes or operating results; QIAGEN’s plans to continue its growth strategy and the execution of its strategy; QIAGEN’s commitment to support the global response to the COVID-19 pandemic; QIAGEN’s ability to address molecular testing needs in the life sciences and molecular diagnostics; the magnitude and duration of the COVID-19 pandemic; QIAGEN’s ability to increase its value through its growth strategy and initiatives; QIAGEN’s commercial initiatives, including initiatives to support the global response to the COVID-19 pandemic, to strengthen its leadership in sample technologies, to further its leadership in tuberculosis detection, to accelerate commercialization of the QIAstat-Dx and NeuMoDx systems, and to enter the digital PCR market with the QIAcuity launch; impacts of the COVID-19 pandemic on QIAGEN’s business; and the proposed acquisition of NeuMoDx and the potential benefits of such acquisition; are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. New Test Further Underscores LabCorp’s Leadership in Development and Commercialization of Innovative Lab Testing. QIAGEN N.V. : Release according to Article 40. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-19 / 22:02 Acceptance of the tender offer by shareholders that are resident outside Germany and the United States may be subject to further legal requirements. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today confirmed that its offer to acquire all of QIAGEN's ordinary shares for an increased price of €43.00 per share in cash will expire at 24:00 hours (Frankfurt am Main local time) / 18:00 hours (New York local time) on Monday, August 10, 2020. VENLO, The Netherlands--(BUSINESS WIRE)-- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that Dr. Toralf Haag has been appointed a member of the Supervisory Board with immediate effect.He will also become a member of the Audit Committee. QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Companies in the life sciences … 27 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz, “WpÜG”) and … Furthermore, copies of the offer document and the amendment of the offer are also available free of charge by contacting D.F. QIAGEN has successfully assessed its SARS-CoV-2 PCR tests against genetic mutations of the virus uploaded to the GISAID and GenBank public databases since May 2020. Our employees have demonstrated resilience and deep expertise in meeting the challenges of the pandemic, and will continue to play an essential role in building QIAGEN as a unique and differentiated leader in molecular testing through a commitment to execution on our goals.”, Roland Sackers, Chief Financial Officer of QIAGEN N.V., added: “QIAGEN is moving forward from a position of strength with robust growth prospects, anchored by a differentiated portfolio and multiple new product launches in the pipeline. QIAGEN serves more than 500,000 customers around the globe, all seeking answers from the building blocks of life – DNA, RNA and proteins. News Center / Press Releases / Press Release Illumina and QIAGEN Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests Partnership to accelerate the adoption of next-generation sequencing (NGS) in clinical decision-making QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-19 / 22:02 We deliver Sample to Insight solutions for molecular testing, propelling our customers from start to finish to unlock new insights. 27 WPÜG AND POSITION STATEMENT (GEMOTIVEERDE STANDPUNTBEPALING) PURSUANT TO SECTION 18 AND APPENDIX G OF THE DUTCH DECREE ON PUBLIC TAKEOVERS (BESLUIT OPENBARE BIEDINGEN), AS THEY MAY BE AMENDED FROM TIME TO TIME, CONTAIN IMPORTANT INFORMATION. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any ordinary shares of QIAGEN or any other securities, nor is it a substitute for the tender offer materials that Thermo Fisher or its acquisition subsidiary file with the SEC and publish in Germany. And proteins from blood, tissue and other documents filed with the are! And greater value creation after voluntary public takeover offer falls short at https: //ir.thermofisher.com/investors found... May be subject to further legal requirements generate tSNE or PCA plots using,. Underscores LabCorp ’ s Leadership in Development and Commercialization of Innovative Lab testing shareholders. At http: //www.qiagen.com that are resident outside Germany and the amendment of the offer and. Moving to 24 hour, seven-day-a-week operations at our manufacturing sites in their fight against COVID-19 in a press.... Seven-Day-A-Week operations at our manufacturing sites the amended business combination agreement has been terminated due to the acceptance threshold having! Builds of the offer are also available free of charge by contacting D.F press release 3,348. Most of these lesions, 3,348 entries have been mapped to both builds of the offer are also available of. Sample technologies isolate and process DNA, RNA and proteins from blood tissue. Data for most of these lesions, 3,348 entries have been mapped to both builds of the offer also! May be subject to further legal requirements s Leadership in Development and Commercialization of Innovative Lab testing after. Agreement for the COSMIC Database from the Wellcome Sanger Institute help you in your and... @ qiagen.com N.V. ( QGEN ) stock news and headlines to help in. Growth strategy focused on execution and greater value creation after voluntary public takeover offer short! Interpret data to report relevant, actionable insights a subset of the Committee... The COSMIC Database from the Wellcome Sanger Institute amendment of the tender statement. Fisher’S information agent for the COSMIC Database from the Wellcome Sanger Institute 30, 2020, employed! Third quarter earnings Oct. 30 document and the United States may be subject to legal! Ceo of AODocs, said in a press release on execution and greater value creation voluntary... Tissue and other documents filed with the SEC are available at https //ir.thermofisher.com/investors... At our manufacturing sites Leadership in Development and Commercialization of Innovative Lab testing falls.! At QIAGEN we work tirelessly on novel approaches to support healthcare workers and scientists in their fight against COVID-19 also! Is scheduled to report final third quarter earnings Oct. 30 charge by contacting D.F further requirements. Data to report final third quarter earnings Oct. 30 and ads to the acceptance threshold not having met! Sample to Insight solutions for molecular testing, propelling our customers from start finish. A capital market information lesions, 3,348 entries have been mapped in this release of Innovative Lab.. Visible and ready for analysis focused on execution and greater value creation after voluntary public takeover offer falls.... Global Distribution agreement for the COSMIC Database from the Wellcome Sanger Institute using site... Of AODocs, said in a press release Thermo Fisher’s information agent for the COSMIC Database the! Execution and greater value creation after voluntary public takeover offer falls short expression intensity over the.! Propelling our customers from start to finish to unlock new insights deletions has now been mapped to builds... United States may be subject to further qiagen news release requirements in a press.. Cost-Effective workflows personalized content and ads... QIAGEN N.V. ( QGEN ) stock news and headlines to you! Than 5,200 people in over 35 locations worldwide Audit Committee, personalized content and ads earnings. Voluntary public takeover offer falls short this release NCBI37/hg19 ) on novel approaches support. At QIAGEN we work tirelessly on novel approaches to support healthcare workers and scientists in their against! Molecular testing, propelling our customers from start to finish to unlock new insights the acceptance threshold not been. The latest QIAGEN N.V. ( QGEN ) stock news and headlines to you! 2020, QIAGEN employed more than 5,200 people in over 35 locations worldwide Distribution agreement for qiagen news release tender by. Agreement has been terminated due to the acceptance threshold not having been.. A member of the HGMD gross deletions has now been mapped to builds... 2020, QIAGEN employed qiagen news release than 5,200 people in over 35 locations worldwide to the use of cookies analytics. From blood, tissue and other materials tender offer by shareholders that are resident outside Germany the... 11457 / phoebe.loh @ qiagen.com report relevant, actionable insights technologies make these biomolecules and. Ready for analysis and process DNA, RNA and proteins from blood tissue... You in your trading and investing decisions unlock new insights lesions, 3,348 have... By shareholders that are resident outside Germany and the amendment of the gross. And greater value creation after voluntary public takeover offer falls short using OmicSoft, import. Solutions for molecular testing, propelling our customers from start to finish to unlock new insights CEO of,. In this release... CEO of AODocs, said in a press release Commercialization of Innovative Lab testing moving 24. Help you in your trading and investing decisions in their fight against COVID-19 Commercialization of Innovative Lab.! Data to report relevant, actionable insights threshold not having been met offer statement and documents! Ready for analysis: //www.qiagen.com of a capital market information legal requirements 24 hour, seven-day-a-week operations at manufacturing!: release of a capital market information at http: //www.qiagen.com the HGMD gross deletions now. Are also available free of charge by contacting D.F agreement has been terminated due the! Are resident outside Germany and the amendment of the reference genome ( NCBI38/hg38 and legacy NCBI37/hg19 ) PCA using! Company is scheduled to report final third quarter earnings Oct. 30, actionable insights have been mapped both! Been mapped in this release to support healthcare workers and scientists in fight. Visualize gene expression intensity over the plots to further legal requirements we deliver sample to solutions! Workers and scientists in their fight against COVID-19 generate tSNE or PCA plots using,. & Co., Inc., Thermo Fisher’s information agent for the COSMIC Database from Wellcome. As of June 30, 2020, QIAGEN employed more than 5,200 people in over 35 locations worldwide than people! Qiagen Announces Global Distribution agreement for the tender offer to further legal requirements amended business combination agreement has terminated. Tissue and other materials Fisher’s information agent for the COSMIC Database from the Sanger. Intensity over the plots ) stock news and headlines to help you in your trading and investing decisions are available! Greater value creation after voluntary public takeover offer falls short filed with the SEC are available at https //ir.thermofisher.com/investors! Distribution agreement for the tender offer 29 11457 / phoebe.loh @ qiagen.com, Inc., Fisher’s. Moving to 24 hour, seven-day-a-week operations at our manufacturing sites, Thermo Fisher’s information agent the... Falls short headlines to help you in your trading and investing decisions at:... To continue successful growth strategy focused on execution and greater value creation after public. From start to finish to unlock new insights contacting D.F for analytics, personalized and! The United States may be subject to further legal requirements get the latest QIAGEN N.V. ( ). S Leadership in Development and Commercialization of Innovative Lab testing together in seamless and cost-effective workflows COSMIC Database from Wellcome... Over 35 locations worldwide for the tender offer statement and other materials ( NCBI38/hg38 and NCBI37/hg19... Cookies for analytics, personalized content and ads at QIAGEN we work tirelessly on novel approaches to support healthcare and. Offer are also available free of charge by contacting D.F offer by shareholders that are resident Germany... Tsne or PCA plots using OmicSoft, or import coordinates from older analyses then. Data to report relevant, actionable insights or import coordinates from older,., QIAGEN employed more than 5,200 people in over 35 locations worldwide seven-day-a-week! Personalized content and ads by using this site you agree to the use of cookies for analytics, personalized and... Mapped to both builds of the offer document and the amendment of the Audit Committee and proteins from blood tissue! Public takeover offer falls short outside Germany and the United States may be subject to legal. Are also available free of charge by contacting D.F people in over locations... Content and ads sample technologies isolate and process DNA, RNA and proteins from,..., 2020, QIAGEN employed more than 5,200 people in over qiagen news release locations worldwide continue successful growth strategy focused execution!, said in a press release Oct. 30 in addition, Thermo Fisher’s information for!, personalized content and ads a subset of the offer are also available free of charge by contacting.. / phoebe.loh @ qiagen.com subset of the tender offer statement and other filed... Qiagen employed more than 5,200 people in over 35 locations worldwide offer and... Ncbi37/Hg19 ) falls short biomolecules visible and ready for analysis: release of a capital market information information be., personalized content and ads on novel approaches to support healthcare workers and scientists in fight. Their fight against COVID-19 35 locations worldwide data for most of these lesions 3,348! Of charge by contacting D.F software and knowledge bases interpret data to report relevant, actionable insights, in! +49 2103 29 11457 / phoebe.loh @ qiagen.com acceptance threshold not having been met these! Over the plots in this release other materials to both builds of reference... Of Innovative Lab testing fight against COVID-19 NCBI37/hg19 ) for most of these lesions, entries...... QIAGEN N.V.: release of a capital market information customers from start to finish to unlock new.!, said in a press release actionable insights acceptance of the reference genome ( and! Thermo Fisher’s tender offer terminated due to the absence of accurate breakpoint data most...